Loneliness is a subjective experience, but neuroscientists define it as a distress that arrives from a discrepancy between perceived and desired social relationships. There may be an evolutionary benefit to the feeling of loneliness; we’re a social species, and feeling lonely might have sent us to seek out other humans, which has been very important for survival. Moreover, if gone unaddressed and isolation worsens, health effects of loneliness have been shown to double mortality rates. It's linked to cardiovascular disease, metabolic disease, cognitive decline, higher rates of dementia, and poor mental health outcomes (i.e. depression and anxiety).With loneliness implicated in so many cognitive impacts, Dr. Lee and her colleagues wanted to understand what is known to date about the impact of loneliness on the brain. They conducted a systematic review of the published research that examines loneliness and resulting neurobiological assessments, such as imaging studies, EEG studies, and pathological studies. Listen in and read to learn more!  See acast.com/privacy for privacy and opt-out information.

Neuropsychopharmacology Podcast

Neurobiology of loneliness: a systematic review

It’s known that dopamine transmission in the brain, particularly in the frontal lobes, can affect decision-making and can regulate choices when it comes to actions and rewards. But the effect of dopamine transition in the medial orbital frontal cortex hasn’t yet been studied, and dysfunction in that region has been implicated in a variety of mental illnesses, including obsessive compulsive disorder, certain kinds of depression, and even schizophrenia. And so a team of researchers led by Stan Floresco, professor of psychology at the University of British Columbia, used a rat model to study the effects of dopamine on two receptors in the region, D1 and D2. To do so, they trained the rats on two games that involved decision-making, and then they infused drugs, one an agonist and one an antagonist, to the brain region. Have a listen!  See acast.com/privacy for privacy and opt-out information.

Medial orbitofrontal cortex dopamine D1/D2 receptors differentially modulate distinct forms of probabilistic decision-making

Nearly 25 years ago, a paper was published about addiction that transformed the field. The director of the US National Institute on Drug Abuse at the time called addiction a “brain disease,” and he wrote a paper articulating this position and the agenda that it implied. It led to a focus on researching the brain to understand the mechanisms behind addiction, which could lead to novel treatments. And it meant that the country began to treat addiction as a disease, thus treating it within the medical system and removing the victim-blaming stigma. Over the years, there has been a pushback against the view of addiction as a brain disease, even within the scientific community. In part, this occurred because research in neuroscience didn’t lead to effective treatments as quickly as the field hoped or promised. And in part, says Markus Heilig, it’s because other researchers felt that funding into the neuroscience of addition meant that other relevant mechanisms, such as social and psychological factors, were perhaps being somewhat neglected. Dr. Heilig and his colleagues recently published a review addressing these and other concerns. Listen in to learn more!  See acast.com/privacy for privacy and opt-out information.

Addiction as a brain disease revised: why it still matters, and the need for consilience

The world of medicine has been changing rapidly due to the increasing use of ‘big data.’ And there’s been a major revolution in this approach in neuroscience and psychiatry as well: computing power, sample sizes, neuroimaging technologies, digital approaches to phenotyping, and computational modeling all are already starting to unleash dramatic new understandings of the brain, as well as new approaches to treatment. And so the journal Neuropsychopharmacology recently published a Reviews issue on the topic of Big Data. Kerry Ressler, chief scientific officer at McLean hospital and professor of psychiatry at Harvard medical school, is one of the editors.  See acast.com/privacy for privacy and opt-out information.

Big data in psychiatry: multiomics, neuroimaging, computational modeling, and digital phenotyping

Interest is growing in the use of the psychedelic drug LSD for psychiatric research and even potentially for treatment. But placebo-controlled studies conducted to date have used just one dose of the drug—none have investigated the impacts of a variety of dosages within the same subjects. In addition, past studies did not use pharmaceutically-defined dosages of LSD, which has made verifying the effects of a particular dose difficult. To address this gap, Matthias Liechti, professor in the department of clinical pharmacology and toxicology at the University of Basel in Switzerland, and his colleagues conducted a study.  See acast.com/privacy for privacy and opt-out information.

Acute dose-dependent effects of lysergic acid diethylamide in a double-blind placebo-controlled study in healthy subjects

Scientists who study neuropsychiatric conditions and treatments often use rodent models to do so. From depression to anxiety to memory impairment and impulsivity, there are certain rodent behaviors that are used to represent these types of conditions in humans. And to use these models, researchers have had to watch the animals live or on video and jot down every instance of, say, exploratory behavior. As the process is labor intensive and results vary slightly from researcher to researcher, Dr. Bohacheck and his colleagues created a new system based on machine learning, and they published the results of their study in the journal Neuropsychopharmacology, along with a review of the field.   See acast.com/privacy for privacy and opt-out information.

Big behavior: challenges and opportunities in a new era of deep behavior profiling

The application of the study of genetics and the use of big data to identify patterns of inheritance as well as de novo mutations has had a dramatic impact on the field of Autism Spectrum Disorder research, and it offers pathways to a greater understanding of biological mechanisms, even potentially treatments. Matthew State, chair of the department of psychiatry at University of California San Francisco, and his colleagues wrote a review paper in the journal Neuropsychopharmacology, called “Leveraging large genomic datasets to illuminate the pathobiology of autism spectrum disorders.” Have a listen to learn more!  See acast.com/privacy for privacy and opt-out information.

Leveraging large genomic datasets to illuminate the pathobiology of autism spectrum disorders

It’s understood in epidemiological research that women who experience trauma during puberty are at significantly higher risk for affective disorders such as depression and anxiety when they become pregnant. And so Tracy Bale, a professor in the departments of psychology and psychiatry at the University of Maryland in Baltimore, has done several studies using mice to try to model and understand this effect. In her latest paper in the journal Neuropsychopharmacology, she and her colleagues set out to study just what was happening to make the mouse brain so vulnerable to stress and trauma during puberty, and how this was activated during the hormonal onslaught of pregnancy.  See acast.com/privacy for privacy and opt-out information.

Pubertal adversity alters chromatin dynamics and stress circuitry in the pregnant brain

Over the past decades, there’s clearly been a dramatic increase in the amount of time people spend online using social networking sites. For instance, Facebook and Instagram have literally billions of users. At the same time, there’s been a rise in mental health issues for young people from teens through their mid 20s. The rise in these issues has been seen particularly for Millennials and the I generation, both of which grew up with increased access to and use of social networking sites. As a result, some have drawn the conclusion that perhaps the two are linked, and the rise in mental health issues is linked causally to the increase in time spent online, and so treatment should involve reducing social networking use. Dr. Kiara Timpano, associate professor at the University of Miami department of psychology, and Dr. Courtney Beard, co-director of the clinical research program in behavioral health at McLean Hospital and associate professor of psychiatry at Harvard Medical School, reviewed the literature.  See acast.com/privacy for privacy and opt-out information.

Social networking and mental health: looking beyond frequency of use and towards mechanisms of action

A number of drugs that are used recreationally are now being studied for their use in psychopharmacology. But while the ways in which these drugs are similar or different has been described anecdotally by recreational users, they haven’t been studied in comparison to one another.&nbsp;Dr. Matthias Liechti&nbsp;and his team of researchers recently published a study in the journal Neuropsychopharmacology, in which 28 healthy subjects, men and women, take doses of LSD, MDMA, amphetamines, and a placebo over four different sessions. Dr. Liechti says this blinding is important; in other studies, participants either have taken a drug or a placebo and can tell when they’re taking the drug. But in this case they don’t know which drug they’re taking, which allows the effects of the drugs to be compared against each other. Take a listen to find out more! For information regarding your data privacy, visit <a href="https://www.acast.com/privacy">acast.com/privacy</a>

A number of drugs that are used recreationally are now being studied for their use in psychopharmacology. But while the ways in which these drugs are similar or different has been described anecdotally by recreational users, they haven’t been studied in comparison to one another.&nbsp;Dr. Matthias Liechti&nbsp;and his team of researchers recently published a study in the journal Neuropsychopharmacology, in which 28 healthy subjects, men and women, take doses of LSD, MDMA, amphetamines, and a placebo over four different sessions. Dr. Liechti says this blinding is important; in other studies, participants either have taken a drug or a placebo and can tell when they’re taking the drug. But in this case they don’t know which drug they’re taking, which allows the effects of the drugs to be compared against each other. Take a listen to find out more! For information regarding your data privacy, visit acast.com/privacy

Distinct acute effects of LSD, MDMA, and D-amphetamine in healthy subjects

It’s known that there’s a relationship between post-traumatic stress disorder, or PTSD, and a higher rate of opioid abuse. What isn’t understood, though, is what that relationship is. Does PTSD cause people to turn to opioids in particular among all the potential drugs of abuse, or is there something about opioid use that makes users particularly sensitive to trauma? This is just what Michael Fanselow, professor in the psychology and psychiatry departments at UCLA, and his colleagues investigated for a recent study in the journal Neuropsychopharmacology. For information regarding your data privacy, visit <a href="https://www.acast.com/privacy">acast.com/privacy</a>

It’s known that there’s a relationship between post-traumatic stress disorder, or PTSD, and a higher rate of opioid abuse. What isn’t understood, though, is what that relationship is. Does PTSD cause people to turn to opioids in particular among all the potential drugs of abuse, or is there something about opioid use that makes users particularly sensitive to trauma? This is just what Michael Fanselow, professor in the psychology and psychiatry departments at UCLA, and his colleagues investigated for a recent study in the journal Neuropsychopharmacology. For information regarding your data privacy, visit acast.com/privacy

Chronic opioid pretreatment potentiates the sensitization of fear learning by trauma

The recreational drug MDMA, also known as Ecstasy or Molly, is particularly popular in social settings and raves, in large part because of how socially connected it makes the users feel. It's being studied for use in psychotherapy — there's a phase III clinical trial for the use of MDMA to treat PTSD. What's clear is that the drug affects how users experience social interactions. But there are questions: Does the drug make positive social interactions feel better, or reduce the negative feelings associated with negative social interactions?<img src="http://feeds.feedburner.com/~r/npp/podcast/current/~4/Ca9pUqvutC8" height="1" width="1" alt=""/> For information regarding your data privacy, visit <a href="https://www.acast.com/privacy">acast.com/privacy</a>

The recreational drug MDMA, also known as Ecstasy or Molly, is particularly popular in social settings and raves, in large part because of how socially connected it makes the users feel. It's being studied for use in psychotherapy — there's a phase III clinical trial for the use of MDMA to treat PTSD. What's clear is that the drug affects how users experience social interactions. But there are questions: Does the drug make positive social interactions feel better, or reduce the negative feelings associated with negative social interactions? For information regarding your data privacy, visit acast.com/privacy

Effects of MDMA on attention to positive social cues and pleasantness of affective touch.

Depression is an incredibly important disorder—according to Thomas Schlaepfer, head of the department of interventional biological psychiatry at the University of Freiburg, at least 20 percent of people have a depressive episode at least once in their lives. And while most patients' symptoms improve with a combination of psychotherapy and medicine, up to 20 percent of depressed patients do not improve from existing treatments. Dr. Schlaepfer and his colleagues have been conducting research on deep brain stimulation, in which implanted electrodes automatically deliver electrical impulses to a particular region of the brain. Have a listen to learn more!<img src="http://feeds.feedburner.com/~r/npp/podcast/current/~4/zimJE92fb60" height="1" width="1" alt=""/> For information regarding your data privacy, visit <a href="https://www.acast.com/privacy">acast.com/privacy</a>

Depression is an incredibly important disorder—according to Thomas Schlaepfer, head of the department of interventional biological psychiatry at the University of Freiburg, at least 20 percent of people have a depressive episode at least once in their lives. And while most patients' symptoms improve with a combination of psychotherapy and medicine, up to 20 percent of depressed patients do not improve from existing treatments. Dr. Schlaepfer and his colleagues have been conducting research on deep brain stimulation, in which implanted electrodes automatically deliver electrical impulses to a particular region of the brain. Have a listen to learn more! For information regarding your data privacy, visit acast.com/privacy

Superolateral medial forebrain bundle deep brain stimulation in major depression: a gateway trial.

Research has demonstrated that, overall, women are more vulnerable to drug addiction than men are. They become addicted more quickly after first using, they have a harder time staying off drugs, and they relapse at higher rates. But most studies have focused on men, and models that have been developed nearly entirely focus on male subjects. Now, two things are changing the situation: scientists are realizing that women's experience and women's brains are different when it comes to addiction, and the NIH has mandated that tests involve female subjects as well. Erin Calipari is assistant professor of pharmacology at the Vanderbilt University School of Medicine, and she's one of the authors of a new paper in the journal Neuropsychopharmacology. In it, she and her colleagues create a new model for examining the differences between female and male rodents when it comes to drug addiction.<img src="http://feeds.feedburner.com/~r/npp/podcast/current/~4/upC1ycVa2Go" height="1" width="1" alt=""/> For information regarding your data privacy, visit <a href="https://www.acast.com/privacy">acast.com/privacy</a>

Research has demonstrated that, overall, women are more vulnerable to drug addiction than men are. They become addicted more quickly after first using, they have a harder time staying off drugs, and they relapse at higher rates. But most studies have focused on men, and models that have been developed nearly entirely focus on male subjects. Now, two things are changing the situation: scientists are realizing that women's experience and women's brains are different when it comes to addiction, and the NIH has mandated that tests involve female subjects as well. Erin Calipari is assistant professor of pharmacology at the Vanderbilt University School of Medicine, and she's one of the authors of a new paper in the journal Neuropsychopharmacology. In it, she and her colleagues create a new model for examining the differences between female and male rodents when it comes to drug addiction. For information regarding your data privacy, visit acast.com/privacy

Cues play a critical role in estrous cycle-dependent enhancement of cocaine reinforcement

Over the past decade, the use of the term 'food addiction' to describe an unhealthy approach to eating has grown. It refers to the idea that, for some people, their inability to control their food intake has similarities to that of a drug of abuse. Paul Kenny is the chair of the Department of Neuroscience at the Icahn School of Medicine in New York. He's one of two authors of a recent circumspective in the journal Neuropsychopharmacology. In the piece, Dr. Kenny and his colleague Dr. Paul Fletcher of the University of Cambridge take opposing viewpoints, Dr. Fletcher arguing against the use of the term food addiction, and Dr. Kenny in favor.<img src="http://feeds.feedburner.com/~r/npp/podcast/current/~4/KIYMSsAD3_Y" height="1" width="1" alt=""/> For information regarding your data privacy, visit <a href="https://www.acast.com/privacy">acast.com/privacy</a>

Over the past decade, the use of the term 'food addiction' to describe an unhealthy approach to eating has grown. It refers to the idea that, for some people, their inability to control their food intake has similarities to that of a drug of abuse. Paul Kenny is the chair of the Department of Neuroscience at the Icahn School of Medicine in New York. He's one of two authors of a recent circumspective in the journal Neuropsychopharmacology. In the piece, Dr. Kenny and his colleague Dr. Paul Fletcher of the University of Cambridge take opposing viewpoints, Dr. Fletcher arguing against the use of the term food addiction, and Dr. Kenny in favor. For information regarding your data privacy, visit acast.com/privacy

Food Addiction: A Valid Concept?

BrainPod is the podcast from the journal Neuropsychopharmacology, produced in association with Nature Publishing Group. Join us as we delve into the latest basic and clinical research that advance our understanding of the brain and behavior, featuring highlighted content from a top journal in fields of neuroscience, psychiatry, and pharmacology. For complete access to the original papers and reviews featured in this podcast, subscribe to Neuropsychopharmacology.

hubhopper

Neuropsychopharmacology Podcast

hubhopper